Evidence map›Paper›PMID 37137947›Full record

ArticleScientific reports2023

External validation of a radiomic signature to predict p16 (HPV) status from standard CT images of anal cancer patients.

Ralph T H Leijenaar, Sean Walsh, Akshayaa Vaidyanathan, Lorenzo Aliboni, Victoria Lopez Sanchez, Michelle Leech, Ronan Joyce, Charles Gillham, Frédéric Kridelka, Roland Hustinx and 6 more

Abstract read
In one paragraph

Article in Scientific reports, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Imaging the hallmarks of cancer.Nature reviews. Cancer · 2026
    Review
  2. Article
  3. Article
  4. HPV-driven cancer: from epidemiology to the HPV-driven tumor board proposal, everything you wanted to know but were afraid to ask.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2025
    Review
  5. Article
  6. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

Ralph T H Leijenaar *Radiomics (Oncoradiomics SA), Liège, Belgium.
Sean Walsh *Radiomics (Oncoradiomics SA), Liège, Belgium.
Akshayaa VaidyanathanRadiomics (Oncoradiomics SA), Liège, Belgium.
Lorenzo AliboniRadiomics (Oncoradiomics SA), Liège, Belgium.
Victoria Lopez SanchezRadiomics (Oncoradiomics SA), Liège, Belgium.
Michelle LeechApplied Radiation Therapy, Discipline of Radiation Therapy, Trinity St. James's Cancer Institute, Trinity College, Dublin, Ireland.
Ronan JoyceDepartment of Radiation Oncology, St. Luke's Radiation Oncology Network and St James's Hospital, Dublin, Ireland.
Charles GillhamDepartment of Radiation Oncology, St. Luke's Radiation Oncology Network and St James's Hospital, Dublin, Ireland.
Frédéric KridelkaDepartment of Obstetrics and Gynecology, University Hospital of Liège, Liège, Belgium.
Roland HustinxDepartment of Nuclear Medicine and Oncological Imaging, University Hospital of Liège, Liège, Belgium.
Denis DanthineDepartment of Nuclear Medicine and Oncological Imaging, University Hospital of Liège, Liège, Belgium.
Mariaelena OcchipintiRadiomics (Oncoradiomics SA), Liège, Belgium.
Wim VosRadiomics (Oncoradiomics SA), Liège, Belgium.
Julien GuiotDepartment of Pneumology, University Hospital of Liège, Liège, Belgium.
Philippe LambinThe D-Lab, Department of Precision Medicine, GROW-School for Oncology and Reproduction, Maastricht University, Maastricht, The Netherlands.
Pierre LovinfosseDepartment of Nuclear Medicine and Oncological Imaging, University Hospital of Liège, Liège, Belgium. pierre.lovinfosse@chuliege.be.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The paper deals with the evaluation of the performance of an existing and previously validated CT based radiomic signature, developed in oropharyngeal cancer to predict human papillomavirus (HPV) status, in the context of anal cancer. For the validation in anal cancer, a dataset of 59 patients coming from two different centers was collected. The primary endpoint was HPV status according to p16 immunohistochemistry. Predefined statistical tests were performed to evaluate the performance of the model. The AUC obtained here in anal cancer is 0.68 [95% CI (0.32-1.00)] with F1 score of 0.78. This signature is TRIPOD level 4 (57%) with an RQS of 61%. This study provides proof of concept that this radiomic signature has the potential to identify a clinically relevant molecular phenotype (i.e., the HPV-ness) across multiple cancers and demonstrates potential for this radiomic signature as a CT imaging biomarker of p16 status.

Indexed as

Anus NeoplasmsOropharyngeal NeoplasmsPapillomavirus InfectionsHuman Papillomavirus VirusesHumansPrognosisRetrospective StudiesTomography, X-Ray Computed

Identifiers

PMID37137947
PMCPMC10156720

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.